Trusted Resource for Clinical Trials, Protocols & Progress
Large-scale clinical trials often involve dozens or even hundreds of investigators spread across different geographies, languages, and time zones. Ensuring that all principal investigators (PIs) remain engaged, aligned, and adequately trained poses a significant operational and compliance challenge.
Click to read the full article.
Investigator meetings are more than just a logistical kickoff for clinical trials—they are formal training events with significant regulatory implications. Agencies such as the FDA, EMA, and others consider these meetings key checkpoints to ensure site readiness, protocol comprehension, and adherence to GCP standards.
Click to read the full article.
In clinical trials, the documentation of attendance and training completion is not a formality—it is a regulatory obligation. Sponsors and CROs must be able to demonstrate that all site personnel, particularly Principal Investigators (PIs), received, understood, and acknowledged essential training on the protocol, Good Clinical Practice (GCP), and study-specific procedures.
Click to read the full article.
As clinical trials become more global and complex, the need for scalable, efficient, and compliant investigator training has intensified. Traditional face-to-face investigator meetings are resource-intensive and often limited by travel, time zones, and scheduling constraints. Enter eLearning—digital training tools that deliver protocol, GCP, and SOP content to site staff ahead of live meetings.
Click to read the full article.
Investigator meetings are essential for aligning study teams across sites, countries, and time zones. However, the true value of these meetings is realized only when sponsors and CROs actively seek and apply feedback to improve future training sessions. Feedback isn’t just about satisfaction—it’s a regulatory-aligned strategy for enhancing comprehension, retention, and operational quality.
Click to read the full article.
Clinical trial success depends not only on robust protocols and efficient recruitment but also on the quality and compliance of site personnel. Regulatory authorities such as the FDA, EMA, and ICH emphasize that all individuals involved in trial conduct must be trained in Good Clinical Practice (GCP) and protocol-specific responsibilities.
Click to read the full article.
In every clinical trial, Principal Investigators (PIs) are not the only ones carrying regulatory responsibility. Study coordinators and Sub-Investigators (Sub-Is) are directly involved in patient care, data entry, drug accountability, and adverse event reporting. These team members must be trained not only in Good Clinical Practice (GCP) but also in study-specific protocols and standard operating procedures (SOPs) aligned to their roles.
Click to read the full article.
Clinical trials have evolved rapidly over the past decade, with remote monitoring, decentralized trial models, and flexible site engagement becoming the norm. In this context, training delivery methods have also transformed—leading to widespread adoption of hybrid training models that combine in-person sessions with virtual modules.
Click to read the full article.
In the eyes of regulators like the FDA, EMA, and ICH, training is not only about attendance—it’s about competence. It’s not enough for site staff to sit through a GCP or protocol presentation. Sponsors and CROs must verify that training leads to actual understanding and performance improvement.
Click to read the full article.
In clinical trials, documenting training is as crucial as delivering it. According to GCP and regulatory authorities like the FDA and EMA, all personnel performing trial-related duties must be qualified and adequately trained. More importantly, this training must be clearly documented, dated, and traceable.
Click to read the full article.
